Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + tiragolumab versus durvalumab after concurrent chemoradiation for unresectable stage III NSCLC
2019-004773-29Phase 3Active
- Sponsor
- Roche
- Start
- Jul 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab + tiragolumab with Durvalumab (2 arms). Primary endpoint: Independent review facility-assessed progression-free survival. Started Jul 2020; status: active.
02
Drugs
atezolizumabtiragolumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-004773-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004773-29.